Spotlight On... Inspectors find big issues at API repackager in France; Vietnam invites Indian drugmakers to build plants; France's Amatsigroup buys Belgian's Q-Biologicals and more...

Sas Jarmat Laboratoire in Reventin Vaugris, France, has stopped its API repackaging operations and recalled all of its products after French inspectors discovered risks for cross-contamination at its facility. According to a report posted by the European Medicines Agency, the company was primarily selling APIs to compounding pharmacies in the Europe. French inspectors noted 21 deficiencies, including three they considered critical, including the possibilities of cross-contamination and the fact that the company was not testing products to see if they met specifications. In fact there were no batch records, they reported. Report

> Vietnam is asking Indian pharmaceutical manufacturers to build plants in that country. Story

> French CDMO Amatsigroup has acquired Belgian-based Q-Biologicals, which provides biologics process development and biomanufacturing services, from research to clinical phase. Report

> CMOs seem to be benefitting from pharma's M&A action. Report

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.